AI Summary
5 min readWhen Moderna announced positive phase 3 results for its personalized mRNA cancer treatment in melanoma, CEO Stéphane Bancel was careful to frame the milestone not as a finish line but as a version 1.0. “The current version of intusmeran is the worst version you’re going to see for the rest of medical history,” he told a16z general partner Jorge Conde. The comment captures an engineer’s humility and a platform company’s ambition. After roughly a thousand failed clinical trials in the cancer vaccine field over 20-plus years, Moderna and Merck have produced the first therapy of its kind that works — and the underlying mechanism suggests this is only the beginning.
Why previous cancer vaccines failed and mRNA succeeded
The idea of training the immune system to attack cancer is not new. The field has run more than a thousand clinical trials on cancer vaccines, and all of them failed. Two things changed with Moderna’s approach.
Continue reading the full summary in the app — free to try.
Read Full Summary →Free • No credit card required
Never miss an episode of a16z Show
Get every new episode summarized in your inbox — free, ~5 minutes to read.
No spam. Unsubscribe anytime.
What you'll learn
- 1 (00:00) **A Historic Milestone in Cancer Treatment** - Stefan Bancel announces positive Phase 3 results for Moderna's personalized mRNA cancer vaccine (intusmeran) in melanoma, calling it "the first time there is a cancer vaccine working" after over a thousand failed clinical trials.
- 2 (06:50) **Why Keytruda Alone Wasn't Enough** - The host asks for a plain-English explanation of why the checkpoint inhibitor Keytruda needed to be paired with the mRNA vaccine, and what the vaccine adds.
- 3 (10:07) **What "Vaccine" Means in This Context** - Clarifying the therapeutic vs. preventive use of the word "vaccine" for cancer patients who already have the disease.
- 4 (11:48) **Why mRNA Succeeded Where 1,000 Previous Trials Failed** - Two key differentiators: the unique mechanism of mRNA delivery and the principle of personalization.
- 5 (13:43) **The Personalization Process: From Biopsy to Injection** - A step-by-step walkthrough of how Moderna creates a bespoke medicine for each patient.
- 6 (15:53) **Inside the Algorithm: How 34 Antigens Are Chosen** - A glimpse into the proprietary "black box" that selects which mutations to target.
- 7 (18:40) **The Operational Challenge: Manufacturing One Patient at a Time** - The host, who has known Bancel since Moderna's early days, asks about the engineering and process obsession required to scale personalized medicine.
+ Full timestamped outline available in the app
Show Notes
a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines.
Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack.
They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases.
Resources:
Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/
Follow Jorge Conde on X: https://x.com/JorgeCondeBio
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More from this podcast
a16z Show →